- Home
- CVM vs NERV Comparison
CVM vs NERV Comparison
Compare CVM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- NERV
- Stock Information
- Founded
- CVM 1983
- NERV 2007
- Country
- CVM United States
- NERV United States
- Employees
- CVM N/A
- NERV N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- NERV Health Care
- Exchange
- CVM Nasdaq
- NERV Nasdaq
- Market Cap
- CVM 11.8M
- NERV 12.0M
- IPO Year
- CVM 1987
- NERV 2014
- Fundamental
- Price
- CVM $3.46
- NERV $1.68
- Analyst Decision
- CVM
- NERV Hold
- Analyst Count
- CVM 0
- NERV 1
- Target Price
- CVM N/A
- NERV $5.00
- AVG Volume (30 Days)
- CVM 1.6M
- NERV 5.6K
- Earning Date
- CVM 08-14-2025
- NERV 08-05-2025
- Dividend Yield
- CVM N/A
- NERV N/A
- EPS Growth
- CVM N/A
- NERV N/A
- EPS
- CVM N/A
- NERV 0.83
- Revenue
- CVM N/A
- NERV N/A
- Revenue This Year
- CVM N/A
- NERV N/A
- Revenue Next Year
- CVM N/A
- NERV N/A
- P/E Ratio
- CVM N/A
- NERV $2.03
- Revenue Growth
- CVM N/A
- NERV N/A
- 52 Week Low
- CVM $1.98
- NERV $1.15
- 52 Week High
- CVM $66.60
- NERV $3.47
- Technical
- Relative Strength Index (RSI)
- CVM 57.66
- NERV 47.97
- Support Level
- CVM $2.24
- NERV $1.59
- Resistance Level
- CVM $2.71
- NERV $1.75
- Average True Range (ATR)
- CVM 0.51
- NERV 0.09
- MACD
- CVM 0.25
- NERV -0.02
- Stochastic Oscillator
- CVM 25.61
- NERV 36.19
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.